EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Genome Editing for Cystic Fibrosis

Guoshun Wang

Cells · 06.06.2023 · 12 (12) · 1555

DOI: 10.3390/cells12121555 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 06.06.2023. Verfasst von Guoshun Wang. Beteiligte Einrichtung: Department of Microbiology, Immunology and Parasitology, Louisiana State University Health Sciences Center, CSRB 607, 533 Bolivar Street, New Orleans…. Hauptthemen laut MEDLINE: Cystic Fibrosis. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 155 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cystic fibrosis (CF) is a monogenic recessive genetic disorder caused by mutations in the CF Transmembrane-conductance Regulator gene (CFTR). Remarkable progress in basic research has led to the discovery of highly effective CFTR modulators. Now ~90% of CF patients are treatable. However, these modulator therapies are not curative and do not cover the full spectrum of CFTR mutations. Thus, there is a continued need to develop a complete and durable therapy that can treat all CF patients once and for all. As CF is a genetic disease, the ultimate therapy would be in-situ repair of the genetic lesions in the genome. Within the past few years, new technologies, such as CRISPR/Cas gene editing, have emerged as an appealing platform to revise the genome, ushering in a new era of genetic therapy. This review provided an update on this rapidly evolving field and the status of adapting the technology for CF therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisHumansCystic Fibrosis Transmembrane Conductance RegulatorGene EditingGenetic TherapyPrecision Medicine

Stichwörter der Autor:innen

CFTRCRISPR/Cascystic fibrosisgene editinggenome editing

Substanzen

Cystic Fibrosis Transmembrane Conductance Regulator

Autor:innen und Institutionen

  • Department of Microbiology, Immunology and Parasitology, Louisiana State University Health Sciences Center, CSRB 607, 533 Bolivar Street, New Orleans, LA 70112, USA.

Förderung

  • NHLBI NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Wang, G. (2023). Genome Editing for Cystic Fibrosis. Cells, 12(12), 1555. https://doi.org/10.3390/cells12121555

Vancouver

Wang G. Genome Editing for Cystic Fibrosis. Cells. 2023;12(12):1555. doi:10.3390/cells12121555

BibTeX
@article{Wang2023,
  author = {Wang, Guoshun},
  title = {Genome Editing for Cystic Fibrosis},
  journal = {Cells},
  year = {2023},
  volume = {12},
  number = {12},
  pages = {1555},
  doi = {10.3390/cells12121555}
}
Kostenlos starten →